After this discovery, additional monoclonal antibodies directed against overexpressed receptor tyrosine kinases or their ligands have been approved for the treatment of cancer, including cetuximab, approved for the treatment of head and neck squamous cell carcinoma (HNSCC) targeting EGFR and bevacizumab (Avastin), which targets the vascular endothelial growth factor A (VEGF-A), a ligand of the VEGF receptor. This evidence concerns the gene EGFR and cancer.